Diagnostics & Biomarkers

About Strykagen

Strykagen is a private, preclinical-stage biotech founded in 2018, targeting significant unmet needs in rare muscular dystrophies including Duchenne (DMD), Becker (BMD), MDC1A, and Limb Girdle types. Its core technology platform centers on stabilizing the muscle extracellular matrix (myomatrix) via biologics and small molecules targeting disease modifiers. Led by a scientifically expert team, the company is building a pipeline of potential therapies and diagnostics, aiming for orphan drug designations to secure market exclusivity for its future products.

Therapeutic Areas